Personalizing ketamine therapy: Real-world predictors of response to IV ketamine and intranasal esketamine in treatment-resistant depression.

Summary

IV ketamine may provide greater antidepressant effects compared to intranasal esketamine, particularly in patients with severe treatment resistance. In a study of 200 adults with treatment-resistant depression, both treatments significantly reduced symptoms, but IV ketamine showed a mean difference of approximately 5 points on the Montgomery-Åsberg Depression Rating Scale (MADRS). Comorbidities, especially borderline personality disorder, negatively impacted treatment response. Personalized treatment approaches considering these profiles are essential.

Study at a glance

Abstract

Treatment-resistant depression (TRD) poses significant clinical challenges, often necessitating alternative treatments such as intravenous (IV) ketamine or intranasal esketamine. This study compared the effectiveness of these modalities and examined predictors of treatment response, including comorbidity profile, prior antidepressant failures, age, and gender. A retrospective chart review was conducted on 200 adults with TRD treated with IV ketamine (median 6 infusions) or intranasal esketamine (median 8 sessions) at a specialized clinic. Depression severity was assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS) and the Patient Health Questionnaire-9 (PHQ-9) at baseline and after acute treatment. Multivariable analyses evaluated the impact of treatment type, psychiatric comorbidities (none, anxiety, PTSD, borderline personality disorder [BPD], multiple), number of failed medications, age, and gender on treatment outcomes. Both treatments significantly reduced depressive symptoms (MADRS mean change: -8.9; PHQ-9: -4, p < 0.0001). IV ketamine produced a greater MADRS reduction than esketamine (mean difference ∼5 points, p = 0.03), especially in highly treatment-resistant patients. Comorbidity profile was a strong moderator: patients without comorbidities experienced the greatest improvement (MADRS -22.0), while those with BPD showed minimal response (MADRS -3.7). Sex had some influence over MADRS outcomes, with males improving more than females (p = 0.03), although no sex difference was evident on the patient-rated PHQ-9 (p = 0.45). Patients age had no effect. IV ketamine may offer superior antidepressant effects compared to esketamine, particularly in patients with severe treatment resistance. However, comorbid psychiatric conditions, especially BPD, attenuate the benefits of both ketamine and esketamine. Personalized approaches considering comorbidity profiles are critical to optimizing outcomes in TRD.

Tags